How can treatment decision-making among patients and health care professionals (HCPs) managing relapsed/refractory multiple myeloma (RRMM) be better understood?
- Treatment decisions based on understanding all treatment options and patients’ goals and experiences are key to building trust between HCPs and patients1
- Aligning treatment with patient preferences could improve adherence and outcomes1
But there may be gaps between what patients and HCPs think are most important for outcomes1
Current understanding of what matters most to patients and HCPs during treatment decision-making is limited1
Few studies compare treatment decision viewpoints of HCPs and patients1
More studies are needed to understand care gaps and find solutions
- Studies are limited by region, line of treatment, or patient age1
- Studies are needed to confirm how care settings affect HCP treatment decisions1
The Unite for MM survey sought to understand treatment decision-making considerations and current barriers to adoption of immunotherapies among patients and HCPs1
Survey goal: Identify care and treatment gaps based on patient and HCP factors1
- Identify similarities and differences in patient and HCP treatment priorities across different countries1
- Understand drivers and barriers to using approved immunotherapies, such as bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies1,2,a
- Uncover opportunities to improve HCP-patient dialogue and treatment decision-making1
aIncludes data from academic/centers of excellence and non-academic (community) settings.1
The online survey engaged a global population of patients with RRMM and HCPs from 7 countries1
- Web-based quantitative surveys designed for patients or HCPs and carried out between March and June 20241
- Participants surveyed in US, UK, France, Germany, Italy, Spain, and Japan1
- Patients with multiple myeloma (MM) aged 18+ years and who had experienced a relapse at least once1
- HCPs: Oncologists and/or hematologists practicing full-time, managing at least 3 patients with MM on second-line or later treatment within 12 months prior to survey, and in practice 4–35 years1
- All data were analyzed using descriptive statistics, chi-square, and stratified chi-square tests, conducted at country level for directional insights1
-
- Participant characteristics described with absolute counts and percentages for categorical variables and standard deviation, median, and range for continuous variables
- P≤.05 considered statistically significant
Reference
- Ailawadhi S, Biru Y, Clavreul S, et al. Perspectives of healthcare providers and patients with relapsed/refractory multiple myeloma on treatment priorities and novel therapies. Patient Prefer Adherence.
2025;19:1089-1104. Published April 2, 2025. Taylor & Francis Ltd. Reprinted by permission of the publisher Informa UK Limited trading as Taylor & Francis Ltd, http://www.tandfonline.com - Banerjee R, Biru Y, Cole CE, Faiman B, Midha S, Ailawadhi S. Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel. Blood Cancer J. 2024;14(1):149.